Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome

Epilepsia. 2018 Sep;59(9):1753-1763. doi: 10.1111/epi.14524. Epub 2018 Aug 22.

Abstract

Objectives: Although secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection-related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities.

Methods: Five patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20-29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation.

Results: Three patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C-X-C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin-1β (IL-1β) and IL-18 were not elevated in any of the samples. Treatment and outcomes were variable.

Significance: We describe 3 patients with HLH and FIRES. The co-occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes.

Keywords: febrile infection-related epilepsy syndrome; hemophagocytic lymphohistiocytosis; refractory status epilepticus.

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Child
  • Child, Preschool
  • Cognition Disorders / etiology
  • Critical Illness
  • Cytokines / blood
  • Cytokines / cerebrospinal fluid
  • Cytokines / metabolism
  • Female
  • Follow-Up Studies
  • HMGB1 Protein / cerebrospinal fluid
  • Humans
  • Immunologic Factors / therapeutic use
  • Lymphohistiocytosis, Hemophagocytic / complications*
  • Lymphohistiocytosis, Hemophagocytic / diagnosis*
  • Lymphohistiocytosis, Hemophagocytic / therapy
  • Male
  • Methylprednisolone / therapeutic use
  • Neopterin / cerebrospinal fluid
  • Seizures, Febrile / complications*
  • Seizures, Febrile / therapy

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • HMGB1 Protein
  • Immunologic Factors
  • Neopterin
  • Methylprednisolone